https://www.selleckchem.com/products/itd-1.html
AIMS To explore the real-world safety and effectiveness of gliclazide modified release (MR) in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan. METHODS DIA-RAMADAN (NCT04132934) was a prospective, international, observational study conducted in nine countries. Patients 18 years of age with T2DM (N=1,244) were examined at an inclusion visit (V occurring 6-8 weeks before the start of Ramadan. Patients received a diary to report treatment changes, hypoglycaemic events (HEs), and other adverse events. Gliclazide MR
Like
Comment
Share
